Cytiva, a global life sciences leader, has partnered with Mycenax Biotech Inc, a leading biopharmaceutical CDMO company, to launch Taiwan’s first continuous bioprocessing lab.
Artiva Biotherapeutics, an oncology company specializing in primary allogeneic natural killer (NK) cell therapies to treat cancer, announced on Aug. 12, 2021 an expansion of its US presence with a new R&D and GMP manufacturing facility in San Diego, Calif., for cell therapies.
New facility at the existing facility in Milford, MA, USA will significantly expand cGMP manufacturing capabilities and accelerate the clinical and commercial supply of vital biopharmaceuticals
Russian researchers from the Moscow Institute of Physics and Technology have developed biosensor chips of unprecedented sensitivity, which are based on copper instead of the conventionally used gold. Besides making the device somewhat cheaper, this innovation will facilitate the manufacturing process.
Bayer Strategic Partnership formed. Bayer and the Broad Institute of MIT and Harvard announced the launch of the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases such as heart failure.
A team of researchers from the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) and UC Berkeley are developing innovative machine learning tools to pull contextual information from scientific datasets and automatically generate metadata tags for each file. Scientists can then search these files via a web-based search engine for scientific data, called Science Search, that the Berkeley team is building.
In our design, self-assembly of MOF nanoparticles and encapsulation of proteins are achieved simultaneously through a one-pot approach in aqueous environment. The enriched metal affinity sites on MOF surfaces act like the buttonhook, so the extracellular vesicle membrane can be easily buckled on the MOF nanoparticles.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656.
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients. Cystic fibrosis is a progressive genetic disorder that results in persistent lung infection and afflicts 30,000 people in the U.S., with about 1,000 new cases diagnosed every year.
Research team discovers drug compound that stops cancer cells from spreading Via a mouse model, OHSU...
Minakem’s HPAPI production will be carried out with an Occupational Exposure Limit (OEL) below 0,1μg/m3/8h. This emphasis on Environment, Health and Safety (EHS) reflects Minakem’s more than 20 years’ experience in continuously monitoring and controlling hazardous working environments, marking its leadership in this area.
Shire plc, the global biotechnology leader in rare diseases, announced today that the United States Food and Drug Administration (FDA) has approved the company’s first submission for its new plasma manufacturing facility near Covington, Georgia for the production of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI).